Mirum Pharmaceuticals
MIRM
272 hedge funds and large institutions have $4.2B invested in Mirum Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 74 funds opening new positions, 91 increasing their positions, 77 reducing their positions, and 14 closing their positions.
429% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 14
49% more capital invested
Capital invested by funds: $2.82B → $4.2B (+$1.38B)
27% more funds holding
Funds holding: 214 → 272 (+58)
18% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 77
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
2.32% more ownership
Funds ownership: 111.83% → 114.15% (+2.3%)
8% less call options, than puts
Call options by funds: $7.16M | Put options by funds: $7.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$42.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.9M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$34.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$33.8M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$80.5M |
| 2 |
JP Morgan Chase
New York
|
-$24.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$23.3M |
| 4 |
Axa
Paris,
France
|
-$17.9M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$15.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAA
276
Affinity Asset Advisors
New York
| – | -$1.26M | -24,692 | Closed |
|
277
Verition Fund Management
Greenwich,
Connecticut
| – | -$1.15M | -22,551 | Closed |
|
|
UOC
278
UBS O'Connor
Chicago,
Illinois
| – | -$1.09M | -21,409 | Closed |
|
|
BAM
279
Bosun Asset Management
Chicago,
Illinois
| – | -$485K | -9,530 | Closed |
|
|
AC
280
AXQ Capital
Jersey City,
New Jersey
| – | -$290K | -5,695 | Closed |
|
281
HSBC Holdings
London,
United Kingdom
| – | -$272K | -5,330 | Closed |
|
282
SG Americas Securities
New York
| – | -$108K | -2,126 | Closed |
|
283
BNP Paribas Asset Management
Paris,
France
| – | -$14K | -274 | Closed |
|
|
SOW
284
State of Wyoming
Cheyenne,
Wyoming
| – | -$10.3K | -202 | Closed |
|
|
SC
285
SouthState Corp
Winter Haven,
Florida
| – | -$2.44K | -48 | Closed |
|
286
Bessemer Group
Woodbridge,
New Jersey
| – | +$127 | +2 | New |
|
MIRM Hedge Fund Activity: Q3 2025 in Review
272 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2025, worth a combined $4.2B — up 49% from $2.82B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new MIRM positions and 14 closed out — a net gain of 60 holders — while 91 added to existing stakes and 77 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $42.7M. The largest seller was BVF Inc, cutting an estimated $80.5M.
- 272 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2025, up from 214 in Q2 2025.
- Funds reported $4.2B of Mirum Pharmaceuticals stock for Q3 2025, up 49% quarter-over-quarter.
- 74 funds opened new Mirum Pharmaceuticals positions in Q3 2025 and 14 closed out, a net change of +60 holders.
- The largest Mirum Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $42.7M added.
- The largest Mirum Pharmaceuticals seller in Q3 2025 was BVF Inc, an estimated $80.5M sold.
Based on aggregated 13F filings for Q3 2025.